Figure 6.

Delivery of CCL2-neutralizing antibodies to tumor-bearing mice increased the levels of human CCL2 in blood and in primary tumor tissues. Tumor-bearing mice were treated with control IgG or CCL2-neutralizing antibodies. Four weeks posttransplantation, ELISAs were performed to measure the levels of (A) human CCL2 in blood, (B) human CCL2 in tumor interstitial fluid, and (C) murine CCL2 in blood. Statistical analysis was performed using two-tailed Student’s t test. Statistical significance was determined by P < .05. **P < .01, ***P < .001, ns = not significant.